The FDA is urged to streamline regulations for new drug manufacturing facilities in the U.S. as part of an executive order signed by President Trump, aimed at expediting construction and enhancing domestic supply. The order also mandates increased inspections of foreign manufacturing plants, funded by higher fees, while requiring the FDA to report inspection data. Major pharmaceutical companies have committed over $170 billion to U.S. manufacturing to mitigate tariff risks. However, building new facilities takes time, and industry leaders warn that tariffs and price controls could deter investment and weaken U.S. competitiveness.

Source: https://www.supplychaindive.com/news/trump-drug-manufacturing-eo-fda-inspection-requirements/747268/